Rumours circulating that Editas has received an offer to be acquired at a valuation of $1.5 bn
jitin001
Posts
-
-
This stock will be trading at $17-20 in a couple of weeks.
-
Massively undervalued stock. Average analyst price target is $16, highest is $30. Crazy that it’s trading at such low levels right now.
-
Stifel analyst Dae Gon Ha upgraded Editas Medicine (NASDAQ: EDIT) from Hold to Buy with a price target of $17.00 (from $9.00).
The analyst comments "We are upgrading EDIT shares to Buy and increasing TP to $17 (vs. $9 previously). We think EDIT-301's (sickle cell disease [SCD]) progress has received minimal credit from investors. But with YE23 goal to dose n=20, in addition to important regulatory insights expected from exa-cel (CRSP, covered by Stifel colleague Ben Burnett), we think EDIT-301 deserves a fresh look. Within, we discuss the disconnect between EDIT and CRSP valuations - at comparable time points in development, EDIT-301's clinical profile thus far (vs. exa-cel), our optimism - both clinically and regulatory - in EDIT-301's strategy (i.e., HBG1/2 promoter region), market receptivity - and TAM - for follow-on gene editing like EDIT-301, and potential upside from the IP dispute.
-
$NVAX investors: I know you are emotionally invested in the company, but consider the facts. $BNTX and $MRNA have sold billions of shots this year and they have a massive order book for ‘22 & ‘23. There is a huge treasure trove of data about their real-world safety and effectiveness. The UK study shows that mRNA boosters are the most effective ones even though others also work. And it is a known fact that with an mRNA platform new versions of the vaccine can be created in a very short period of time, so mutations can be dealt with. In comparison, $NVAX hasn’t even applied for FDA approval as yet, has made no actual deliveries, and is known to be struggling with production issues except through SII. And SII won’t get approval in India until FDA approves; also SII’s ability to export outside India is determined by the govt of India. If omicron spreads in India they will quickly ban all exports as they did earlier this year.
-
$BNTX shareholders are extremely weak minded. That is the main reason why the stock is unable to rise to its true value. Market cap of $BNTX should be at least equal to, in fact significantly higher than, that of $MRNA. So the stock price should not just be higher than $MRNA, it should actually be twice. But the shareholders are too fickle-minded.
-
$BNTX Bears are at it again trying to play psychological games to instil fear, uncertainty and doubt through random negative comments. Wonder who are the weak-kneed investors who get affected by such crap. It’s absolutely pathetic. Stay strong investors. Don’t fall for the BS. This stock is massively undervalued. Just to catch up with the current $MRNA valuation, $BNTX should be trading at $475+. And $MRNA itself has a lot of upside. Boosters will become an annual market - UK has already signalled this and other countries will follow. The only reason why PE multiple is so low is the uncertainty about ongoing revenues, and once this uncertainly is removed the PE ratio should get closer to market average of 20+. That means the stock is worth at least $800. Stop day trading. Buy and hold. Be patient. Let the impatient transfer their wealth to you.
-
$BNTX PEOPLE NEED TO STOP PANIC SELLING AND THIS STOCK WILL SHOOT UP. ALL THE FUNDAMENTALS ARE ROCK SOLID. IGNORE THE DAILY AND HOURLY SWINGS. LET MOMENTUM BUILD. IF YOU SIMPLY HOLD THE SKY IS THE LIMIT.
-
STOP SELLING!! Let the momentum build. This stock has only one way to go.
-
Seriously.. who are the idiots who keep selling??
-
$BNTX Who are the idiots who keep selling and dragging down the momentum. You are not investors or traders, you are just suckers who will get chewed up eventually. #heightofstupidity #diamondhands
-
Full FDA approval for $BNTX is a big deal because it shows that FDA has analysed 9 months’ of real world data about vaccine safety and efficacy and concluded that it is safe and it works. This will put to bed all speculation about safety and efficacy arising out of various studies that keep popping up. The amount of data that FDA would have studied in its analysis dwarfs any other studies conducted here and there. The only reason $BNTX price dropped suddenly and substantially after spectacular Q2 results is doubt about vaccine efficacy created by these studies. All such doubt should now disappear. Most analysts have raised the price target to $430-450, and many believe that the fair value is $600+. Time for the market to get moving. $BNTX investors, HODL! Do not sell a single share till we cross $450.
-
Bears are trying desperately to dampen sentiment by recycling the same story again and again - that vaccine efficacy drops over time. What they don’t understand is that from vaccine sales point of view (and hence from stock price point of view) this is a good thing. There will be an ongoing market for booster shots and it will be dominated by $BNTX and $MRNA.
-
Novavax insiders busy selling while the suckers here are HODLing.. lol
-
There is no fathomable reason for $BNTX valuation to be only 62% that of $MRNA. BionTech might be splitting its revenue with Pfizer/ Fosun but it is also selling 4 times Moderna. Half of 4x revenue is still 2x revenue. At minimum $BNTX should have the same market cap as $MRNA. That means it’s stock should be 1.5x present levels, around $350, just to have the same valuation as Moderna. Huge upside sitting here with minimal risk.
EDIT
EDIT
EDIT
EDIT
EDIT
NVAX
NVAX
BNTX
BNTX
BNTX
BNTX
BNTX
BNTX
BNTX
BNTX
BNTX
BNTX
MRNA
NVAX
BNTX